Trial Profile
An Open-label, Multiple-dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs SR T100 (Primary)
- Indications Actinic keratosis
- Focus Pharmacokinetics
- Sponsors G&E Herbal Biotechnology
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 31 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.